HK1141008A1 - 嘌呤基衍生物及其作為鉀通道調節劑的用途 - Google Patents

嘌呤基衍生物及其作為鉀通道調節劑的用途

Info

Publication number
HK1141008A1
HK1141008A1 HK10107002.9A HK10107002A HK1141008A1 HK 1141008 A1 HK1141008 A1 HK 1141008A1 HK 10107002 A HK10107002 A HK 10107002A HK 1141008 A1 HK1141008 A1 HK 1141008A1
Authority
HK
Hong Kong
Prior art keywords
potassium channel
channel modulators
purinyl derivatives
purinyl
derivatives
Prior art date
Application number
HK10107002.9A
Other languages
English (en)
Inventor
‧埃裡克森
‧瑟倫森
‧霍高
‧彼得斯
‧約翰森
‧克裡斯托弗森
Original Assignee
有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 有限責任公司 filed Critical 有限責任公司
Publication of HK1141008A1 publication Critical patent/HK1141008A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10107002.9A 2007-03-28 2010-07-20 嘌呤基衍生物及其作為鉀通道調節劑的用途 HK1141008A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90850307P 2007-03-28 2007-03-28
DKPA200700482 2007-03-28
PCT/EP2008/053648 WO2008116909A1 (en) 2007-03-28 2008-03-27 Purinyl derivatives and their use as potassium channel modulators

Publications (1)

Publication Number Publication Date
HK1141008A1 true HK1141008A1 (zh) 2010-10-29

Family

ID=39473604

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107002.9A HK1141008A1 (zh) 2007-03-28 2010-07-20 嘌呤基衍生物及其作為鉀通道調節劑的用途

Country Status (8)

Country Link
US (4) US20100130516A1 (zh)
EP (5) EP2142545A1 (zh)
AU (1) AU2008231695B2 (zh)
CA (1) CA2682019C (zh)
HK (1) HK1141008A1 (zh)
IL (1) IL200501A0 (zh)
MX (1) MX2009010122A (zh)
WO (5) WO2008116910A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
JP2010517970A (ja) * 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
CN101646669B (zh) * 2007-03-28 2013-09-04 神经研究公司 嘌呤基衍生物及其作为钾通道调节剂的用途
WO2008116910A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
US8158624B2 (en) 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
JP2012501308A (ja) * 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
US8765770B2 (en) 2009-04-01 2014-07-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
US20120184517A1 (en) * 2009-04-30 2012-07-19 Steven Marx Treatment of diseases with altered smooth muscle contractility
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
MX2013000389A (es) 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
TW201500358A (zh) 2010-12-16 2015-01-01 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN102351716B (zh) * 2011-08-17 2013-11-06 中国石油化工股份有限公司 一种降低甲酰苯胺法制备对氨基二苯胺塔设备腐蚀的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
WO2015005491A1 (ja) * 2013-07-12 2015-01-15 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
EP3226861A2 (en) 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Compounds for treating cystic fibrosis
SI3303330T1 (sl) 2015-06-03 2019-08-30 Bristol-Myers Squibb Company Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
EP3341372A1 (en) * 2015-08-25 2018-07-04 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CA3026149A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
DK3571193T3 (da) 2017-01-23 2022-01-17 Cadent Therapeutics Inc Potassium Channel Modulators
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN116178374A (zh) * 2023-01-13 2023-05-30 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
CA2394646A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
DE60031886T2 (de) 1999-12-17 2007-09-06 Ariad Pharmaceuticals, Inc., Cambridge Purinderivate
IL150062A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
ATE301123T1 (de) 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2003031406A2 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20060009642A1 (en) * 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
AU2003254053A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265636A1 (en) * 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2006097441A1 (en) 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US20090036475A1 (en) * 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2008534472A (ja) 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
EP1881991A1 (en) * 2005-05-19 2008-01-30 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007071632A2 (en) * 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
TW200745847A (en) * 2005-12-23 2007-12-16 Koninkl Philips Electronics Nv Apparatus and method for dynamic cache management
WO2008028935A2 (en) 2006-09-07 2008-03-13 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
EP2074113A1 (en) 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
AU2008210904A1 (en) * 2007-01-26 2008-08-07 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of Plasmodium related diseases
JP2010517970A (ja) * 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
WO2008116910A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
CN101646669B (zh) * 2007-03-28 2013-09-04 神经研究公司 嘌呤基衍生物及其作为钾通道调节剂的用途
EA201000614A1 (ru) * 2007-10-17 2010-10-29 Новартис Аг Производные пурина как лиганды аденозинового рецептора а
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US8268838B2 (en) * 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas

Also Published As

Publication number Publication date
EP2142545A1 (en) 2010-01-13
MX2009010122A (es) 2009-10-19
WO2008116912A2 (en) 2008-10-02
US20100130516A1 (en) 2010-05-27
WO2008116910A1 (en) 2008-10-02
US20100152210A1 (en) 2010-06-17
EP2142547A1 (en) 2010-01-13
WO2008116909A1 (en) 2008-10-02
WO2008116914A1 (en) 2008-10-02
EP2144911A2 (en) 2010-01-20
IL200501A0 (en) 2010-04-29
EP2142546B1 (en) 2017-06-07
EP2132208A1 (en) 2009-12-16
US8362024B2 (en) 2013-01-29
AU2008231695B2 (en) 2013-03-28
US20130109704A1 (en) 2013-05-02
EP2142546A1 (en) 2010-01-13
US9340544B2 (en) 2016-05-17
WO2008116912A3 (en) 2009-02-05
CA2682019A1 (en) 2008-10-02
AU2008231695A1 (en) 2008-10-02
US20100120797A1 (en) 2010-05-13
CA2682019C (en) 2016-08-09
WO2008116911A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
HK1141008A1 (zh) 嘌呤基衍生物及其作為鉀通道調節劑的用途
ZA200905796B (en) Purinyl derivatives and their use as potassium channel modulators
AP2516A (en) 2-Pyridine carboxamide derivatives as sodium channel modulators
ZA201000436B (en) Novel esterases and their use
EP2178373A4 (en) HETEROCYCLES AS COLD CHANNEL MODULATORS
GB0701426D0 (en) Compounds and their use
GB0700580D0 (en) Use
HK1147968A1 (zh) 作為刺猬蛋白信號通路調節劑的聯苯基甲酰胺類化合物
GB0723794D0 (en) Potassium ion channel modulators and uses thereof
PT2194783T (pt) Composições e métodos para moduladores da apoptose
EP2129680A4 (en) COMBINED HAIR-ANTISENSE HAIR LOOP COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION
IL208771A0 (en) Iminopyridine derivatives and use thereof
SI2170861T1 (sl) Derivati 4-(n-azacikloalkil) anilidov kot kalijevi kanalski modulatorji
EP2170874A4 (en) NEW COMPOUNDS AND THEIR USE
PT2027842E (pt) Produto absorvente
EP2174629A4 (en) BUFFER
GB0724246D0 (en) Noval use
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
EP2310369A4 (en) BENZYL OXYANILID DERIVATIVES SUITABLE AS SODIUM CHANNEL MODULATORS
GB0701096D0 (en) Use
GB2454741B (en) Wristband
GB0711036D0 (en) Composition and their use
GB0722678D0 (en) Compounds and their use II
GB0725186D0 (en) Learners mate
AU2007905398A0 (en) Novel cobalamins and use thereof